The studies published so far included patients with evidence of NTRK rearrangements based on immunohistochemistry (IHC), FISH or RNA/DNA sequencing methods, and some studies only required a tumour to be ‘positive for a molecular alteration’ of NTRK1‐34, 5 (http://clinicaltrials.gov number: NCT02097810, NCT02568267, NCT02122913, NCT02576431 and NCT02637687). The gene discussed is NTRK1; the disease is neoplasm.